Molnupiravir drug against coronavirus revealed 30% less effective in decreasing the risk of hospitalization and deaths, revealed Merck's updated data.
Commercial COVID-19 Drug Production In India
Biocon Biologics signed a pact with Adagio Therapeutics for manufacturing antibody-based COVID-19 treatment that can effectively neutralize a broad range of COVID-19 variants in India.
Biocon Biologics signed a pact with Adagio Therapeutics for manufacturing antibody-based COVID-19 treatment that can effectively neutralize a broad range of COVID-19 variants in India.
‘According to the interim data released by Merck the molnupiravir pill was 50 per cent able to reduce hospitalizations and deaths in 775 patients.’
A planned interim analysis of the data last month showed that 7.3 per cent of those given molnupiravir twice a day for five days were hospitalised and none had died by 29 days after the treatment. That compared with a hospitalisation rate of 14.1 per cent for placebo patients. In the updated data, 6.8 per cent of those given molnupiravir were hospitalised and one person died, while the other placebo group had a hospitalisation rate of 9.7 per cent.
So far, the UK is the only country to grant a conditional authorisation to Merck's Covid pill.
EU Signs 63m Euro Deal to Secure Supplies of COVID-19 Drug Remdesivir
European Commission has signed a contract with American pharmaceutical company Gilead to secure doses of Veklury, the brand name for Remdesivir, for the COVID-19 treatment.
European Commission has signed a contract with American pharmaceutical company Gilead to secure doses of Veklury, the brand name for Remdesivir, for the COVID-19 treatment.
Molnupiravir is also pending review at regulators in Europe and other countries.
Advertisement
New Radical COVID-19 Drug Development Approach Holds Promise
University of Washington's Baker Lab uses de novo computational design on TACC systems to create new therapeutic approach for treating novel coronavirus.
University of Washington's Baker Lab uses de novo computational design on TACC systems to create new therapeutic approach for treating novel coronavirus.
Source-IANS
COVID-19 Drug Development Could be Easier With Approach Used Against Flu
A new study from researchers at the University of Texas at Austin has found that some antivirals are useful in preventing deaths if used early.
A new study from researchers at the University of Texas at Austin has found that some antivirals are useful in preventing deaths if used early.
